- Thinly traded nano cap Repros Therapeutics (NASDAQ:RPRX) is up 16% after hours on increased volume in response to its announcement of positive results from two Phase 2 studies assessing oral and vaginal delivery of Proellex (telapristone acetate) for the treatment of uterine fibroids.
- Both studies enrolled women with confirmed fibroids at baseline and experiencing more than 80 mL of blood loss during menses. Participants were administered both 6 mg and 12 mg doses, by either route for 18 weeks followed by a treatment-free phase to allow for menses. After menses occurred, a second 18-week course of treatment was conducted.
- At the end of the second course of treatment, 92.9% of subjects treated with oral Proellex achieved amenorrhea (absence of menstruation) while only 50% of the vaginally treated group did. In the orally administered group, 100% of subjects receiving the 12 mg dose achieved amenorrhea while 88.9% of the 6 mg group stopped menses.
- The company intends to advance orally administered Proellex to Phase 3 development.
-
Proellex is a small molecule compound that selectively blocks the progesterone receptor.